Response to Letter to the Editor Titled "The Impact of Patient Characteristics on Tumor Cell PD-L1 Expression in NSCLC Patients"
J Thorac Oncol
.
2019 Sep;14(9):e212-e213.
doi: 10.1016/j.jtho.2019.06.022.
Authors
Anne-Marie Boothman
1
,
Jill Walker
2
Affiliations
1
Precision Medicine and Genomics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. Electronic address:
[email protected]
.
2
Precision Medicine and Genomics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
PMID:
31445744
DOI:
10.1016/j.jtho.2019.06.022
No abstract available
Publication types
Letter
Comment
MeSH terms
Apoptosis
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Programmed Cell Death 1 Receptor
Substances
B7-H1 Antigen
Programmed Cell Death 1 Receptor